GARBARINO, OMBRETTA
 Distribuzione geografica
Continente #
EU - Europa 1.230
AS - Asia 5
NA - Nord America 2
Totale 1.237
Nazione #
IT - Italia 1.230
CN - Cina 3
SG - Singapore 2
US - Stati Uniti d'America 2
Totale 1.237
Città #
Genoa 542
Genova 429
Rapallo 164
Vado Ligure 94
Ashburn 2
Singapore 2
Beijing 1
Bordighera 1
Totale 1.235
Nome #
Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation 165
MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance 132
Targeting CD44/xCT is a potential strategy to sensitize human neuroblastoma stem cells to etoposide 130
Glutathione and the switch of aerobic metabolism collaborate for multi-drug resistance of neuroblastoma 129
Pkcα inhibition as a strategy to sensitize neuroblastoma stem cells to etoposide by stimulating ferroptosis 110
CD44/xCT inhibition is a potential strategy to sensitize cancer stem cells to etoposide pro-oxidant effects 106
Investigating PLX4032 resistance in a human melanoma cell line: a question of metabolism 98
Characterization of metabolic and molecular response of a human melanoma cell line resistant to PLX4032 97
Biological evaluation of pyrazolyl-urea and dihydro-imidazopyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma 96
PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism 82
xCT/CD44 modulation induces the sensitization of neuroblastoma-stem cells to etoposide. 75
Erratum: Correction: Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma (Oncotarget) 50
Totale 1.270
Categoria #
all - tutte 4.998
article - articoli 4.667
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.665


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202168 0 0 0 6 11 4 7 13 6 8 8 5
2021/2022154 9 8 3 38 13 15 2 24 9 13 2 18
2022/2023199 11 21 3 29 19 28 0 14 25 0 45 4
2023/2024131 4 10 5 22 28 17 3 7 2 13 9 11
2024/2025312 11 16 1 35 18 22 35 64 10 13 44 43
2025/2026175 74 8 45 48 0 0 0 0 0 0 0 0
Totale 1.270